Fully diluted the market cap is $12,000,000. If tesetaxel actually worked as well as the other taxanes, this would be undervalued. But even if Tesetaxel became the taxane of choice, Genta would need a lot more financing to fund the trials.
Way too much risk here, but genta always seems to run 5x to 10x at some point. It probably will again soon. Looks like it's finally bottoming out.